Custom-Made vaccine targets deadly brain cancer in tiny pilot trial

NCT ID NCT04015700

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a personalized DNA vaccine designed to train the immune system to attack glioblastoma, a fast-growing brain cancer. Nine patients with a specific type of glioblastoma (unmethylated MGMT) received the vaccine along with an immune booster. The main goals were to see if the vaccine was safe, could be made quickly enough, and triggered an immune response. Results are still being analyzed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Personalized neoantigen DNA vaccine (GNOS-PV01) plus IL-12 plasmid, delivered via electroporation device
What this could lead to
If successful, this could point toward a personalized immune-based treatment for glioblastoma, potentially extending survival.
What could go wrong
This is a very early (Phase 1) pilot study with only 9 participants. The vaccine may not trigger a strong enough immune response, and side effects could be significant. Many early cancer vaccines fail to show benefit in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.